{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,29]],"date-time":"2024-07-29T03:05:50Z","timestamp":1722222350615},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"published-print":{"date-parts":[[2006,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Although described by Hippocrates in 400 B.C., pemphigus disease still needs a safe therapeutical approach, given that the currently used therapies (i.e. corticosteroids and immunosuppressive drugs) often provoke collateral effects. Here we present preliminary data on the possible use of a proteomics derived desmoglein peptide which appears promising in halting disease progression without adverse effects.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>The low-similarity Dsg3<jats:sub>49\u201360<\/jats:sub>REWVKFAKPCRE peptide was topically applied for 1 wk onto a lesion in a patient with a late-stage Pemphigus vulgaris (PV) complicated by diabetes and cataract disease. The peptide was applied as an adjuvant in combination with the standard corticosteroid-based immunosuppressive treatment.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>After 1 wk, the treated PV eroded lesion appeared dimensionally reduced and with an increased rate of re-epithelization when compared to adjacent non-treated lesions. Short-term benefits were: decrease of anti-Dsg antibody titer and reduction of the corticosteroid dosage. Long-term benefits: after two years following the unique 1-wk topical treatment, the decrease of anti-Dsg antibody titer persists. The patient is still at the low cortisone dosage. Adverse effects: no adverse effect could be monitored.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>With the limits inherent to any preliminary study, this case report indicates that topical treatment with Dsg3<jats:sub>49\u201360<\/jats:sub>REWVKFAKPCRE peptide may represent a feasible first step in the search for a simple, effective and safe treatment of PV.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/1479-5876-4-43","type":"journal-article","created":{"date-parts":[[2006,10,25]],"date-time":"2006-10-25T00:57:40Z","timestamp":1161737860000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Preliminary data on Pemphigus vulgaris treatment by a proteomics-defined peptide: a case report"],"prefix":"10.1186","volume":"4","author":[{"given":"Giovanni","family":"Angelini","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Domenico","family":"Bonamonte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alberta","family":"Lucchese","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gianfranco","family":"Favia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosario","family":"Serpico","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abraham","family":"Mittelman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simone","family":"Simone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Animesh A","family":"Sinha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Darja","family":"Kanduc","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2006,10,24]]},"reference":[{"key":"148_CR1","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1111\/j.1365-4362.1988.tb00937.x","volume":"27","author":"K Holubar","year":"1988","unstructured":"Holubar K: Pemphigus: a disease of man and animal. Historical and other perspectives. Int J Dermatol. 1988, 27: 516-520.","journal-title":"Int J Dermatol"},{"key":"148_CR2","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/0738-081X(83)90019-6","volume":"1","author":"DF King","year":"1983","unstructured":"King DF, Holubar K: History of pemphigus. Clin Dermatol. 1983, 1: 6-12. 10.1016\/0738-081X(83)90019-6.","journal-title":"Clin Dermatol"},{"key":"148_CR3","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1016\/0092-8674(91)90360-B","volume":"67","author":"M Amagai","year":"1991","unstructured":"Amagai M, Klaus-Kovtun V, Stanley JR: Autoantibodies against a novel epithelial cadherin in pemphigus vulgaris, a disease of cell adhesion. Cell. 1991, 67: 869-877. 10.1016\/0092-8674(91)90360-B.","journal-title":"Cell"},{"key":"148_CR4","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1006\/clin.1997.4408","volume":"85","author":"JM Mascaro Jr","year":"1997","unstructured":"Mascaro JM, Espana A, Liu Z, Ding X, Swartz SJ, Fairley JA, Diaz LA: Mechanisms of acantholysis in Pemphigus vulgaris: role of IgG valence. Clin Immunol Immunopathol. 1997, 85: 90-96. 10.1006\/clin.1997.4408.","journal-title":"Clin Immunol Immunopathol"},{"key":"148_CR5","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1111\/j.1346-8138.2001.tb00054.x","volume":"28","author":"JR Stanley","year":"2001","unstructured":"Stanley JR: Pathophysiology and therapy of pemphigus in the 21st century. J Dermatol. 2001, 28: 645-646.","journal-title":"J Dermatol"},{"key":"148_CR6","doi-asserted-by":"publisher","first-page":"S21","DOI":"10.1016\/j.jaad.2004.02.006","volume":"51","author":"M Rogul","year":"2004","unstructured":"Rogul M: Pemphigus: hard to diagnose and treat. J Am Acad Dermatol. 2004, 51: S21-22. 10.1016\/j.jaad.2004.02.006.","journal-title":"J Am Acad Dermatol"},{"key":"148_CR7","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1111\/j.1365-2133.2003.05665.x","volume":"149","author":"KE Harman","year":"2003","unstructured":"Harman KE, Albert S, Black MM: British Association of Dermatologists. Guidelines for the management of pemphigus vulgaris. Br J Dermatol. 2003, 149: 926-937. 10.1111\/j.1365-2133.2003.05665.x.","journal-title":"Br J Dermatol"},{"key":"148_CR8","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1046\/j.1468-3083.2002.00504.x","volume":"16","author":"S Ljubojevic","year":"2002","unstructured":"Ljubojevic S, Lipozencic J, Brenner S, Budimcic D: Pemphigus vulgaris: a review of treatment over a 19-year period. J Eur Acad Dermatol Venereol. 2002, 16: 599-603. 10.1046\/j.1468-3083.2002.00504.x.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"148_CR9","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1046\/j.1468-3083.2002.00413.x","volume":"16","author":"GG Toth","year":"2002","unstructured":"Toth GG, van de Meer JB, Jonkman MF: Dexamethasone pulse therapy in pemphigus. J Eur Acad Dermatol Venereol. 2002, 16: 607-611. 10.1046\/j.1468-3083.2002.00413.x.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"148_CR10","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1067\/S0190-9622(03)00859-4","volume":"49","author":"DL Cummins","year":"2003","unstructured":"Cummins DL, Mimouni D, Anhalt GJ, Nousari CH: Oral cyclophosphamide for treatment of pemphigus vulgaris and foliaceus. J Am Acad Dermatol. 2003, 49: 276-280. 10.1067\/S0190-9622(03)00859-4.","journal-title":"J Am Acad Dermatol"},{"key":"148_CR11","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1007\/s00105-003-0594-2","volume":"54","author":"T Assmann","year":"2003","unstructured":"Assmann T, Voss R, Ruzicka T, Megahed M: Therapy resistant pemphigus vulgaris. Combination therapy with methylprednisolone and doxycycline. Hautarzt. 2003, 54: 979-981. 10.1007\/s00105-003-0594-2.","journal-title":"Hautarzt"},{"key":"148_CR12","first-page":"13","volume":"130","author":"C Benoit Corven","year":"2003","unstructured":"Benoit Corven C, Carvalho P, Prost C, Verret JL, Saiag P, Noblesse I, Bedane C, Chosidow O, Young P, Roujeau JC, Joly P: Treatment of pemphigus vulgaris by azathioprine and low doses of prednisone (Lever scheme). Ann Dermatol Venereol. 2003, 130: 13-15.","journal-title":"Ann Dermatol Venereol"},{"key":"148_CR13","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/S1473-0502(02)00095-2","volume":"28","author":"G Mazzi","year":"2003","unstructured":"Mazzi G, Raineri A, Zanolli FA, Da Ponte C, De Roia D, Santarossa L, Guerra R, Orazi BM: Plasmapheresis therapy in pemphigus vulgaris and bullous pemphigoid. Transfus Apheresis Sci. 2003, 28: 13-18. 10.1016\/S1473-0502(02)00095-2.","journal-title":"Transfus Apheresis Sci"},{"key":"148_CR14","first-page":"377","volume":"13","author":"N Sami","year":"2003","unstructured":"Sami N, Bhol KC, Ahmed RA: Influence of intravenous immunoglobulin therapy on autoantibody titers to desmoglein 3 and desmoglein 1 in pemphigus vulgaris. Eur J Dermatol. 2003, 13: 377-381.","journal-title":"Eur J Dermatol"},{"key":"148_CR15","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1001\/archderm.138.9.1158","volume":"138","author":"N Sami","year":"2002","unstructured":"Sami N, Qureshi A, Ruocco E, Ahmed AR: Corticosteroid-sparing effect of intravenous immunoglobulin therapy in patients with pemphigus vulgaris. Arch Dermatol. 2002, 138: 1158-1162. 10.1001\/archderm.138.9.1158.","journal-title":"Arch Dermatol"},{"key":"148_CR16","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1046\/j.1365-2249.2002.01967.x","volume":"129","author":"S Jolles","year":"2002","unstructured":"Jolles S: High-dose intravenous immunoglobulin (hdIVIg) in the treatment of autoimmune blistering disorders. Clin Exp Immunol. 2002, 129: 385-389. 10.1046\/j.1365-2249.2002.01967.x.","journal-title":"Clin Exp Immunol"},{"key":"148_CR17","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1067\/mjd.2002.122735","volume":"47","author":"JC Bystryn","year":"2002","unstructured":"Bystryn JC, Jiao D, Natow S: Treatment of pemphigus with intravenous immunoglobulin. J Am Acad Dermatol. 2002, 47: 358-363. 10.1067\/mjd.2002.122735.","journal-title":"J Am Acad Dermatol"},{"key":"148_CR18","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1001\/archderm.140.3.327","volume":"140","author":"VT Nguyen","year":"2004","unstructured":"Nguyen VT, Arredondo J, Chernyavsky AI, Pittelkow MR, Kitajima Y, Grando SA: Pemphigus vulgaris acantholysis ameliorated by cholinergic agonists. Arch Dermatol. 2004, 140: 327-334. 10.1001\/archderm.140.3.327.","journal-title":"Arch Dermatol"},{"key":"148_CR19","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1111\/j.1346-8138.2003.tb00464.x","volume":"30","author":"R Jain","year":"2003","unstructured":"Jain R, Kumar B: Immediate and delayed complications of dexamethasone cyclophosphamide pulse(DCP) therapy. J Dermatol. 2003, 30: 713-718.","journal-title":"J Dermatol"},{"key":"148_CR20","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1345\/aph.1A047","volume":"36","author":"GG Toth","year":"2002","unstructured":"Toth GG, Westerlaken BO, Eilders M, Laseur M, Jonkman MF, Uges DR: Dexamethasone pharmacokinetics after high-dose oral therapy for pemphigus. Ann Pharmacother. 2002, 36: 1108-1109. 10.1345\/aph.1A047.","journal-title":"Ann Pharmacother"},{"key":"148_CR21","doi-asserted-by":"publisher","first-page":"165","DOI":"10.2334\/josnusd.45.165","volume":"45","author":"EE Sakallioglu","year":"2003","unstructured":"Sakallioglu EE, Acikgoz G, Keles G, Senturk N, Karagoz F: Pemphigus vulgaris and complications of systemic corticosteroid therapy: a case report. J Oral Sci. 2003, 45: 165-169.","journal-title":"J Oral Sci"},{"key":"148_CR22","doi-asserted-by":"publisher","first-page":"239","DOI":"10.2174\/157016305775202946","volume":"2","author":"D Kanduc","year":"2005","unstructured":"Kanduc D: Peptimmunology: immunogenic peptides and sequence redundancy. Curr Drug Discov Technol. 2005, 2: 239-244. 10.2174\/157016305775202946.","journal-title":"Curr Drug Discov Technol"},{"key":"148_CR23","doi-asserted-by":"publisher","first-page":"33","DOI":"10.2174\/157016006776055374","volume":"4","author":"D Kanduc","year":"2006","unstructured":"Kanduc D: Defining peptide sequences: from antigenicity to immunogenicity through redundancy. Curr Pharmacogenomics. 2006, 4: 33-37. 10.2174\/157016006776055374.","journal-title":"Curr Pharmacogenomics"},{"key":"148_CR24","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1016\/S0196-9781(99)00095-9","volume":"20","author":"J Willers","year":"1999","unstructured":"Willers J, Lucchese A, Kanduc D, Ferrone S: Molecular mimicry of phage displayed peptides mimicking GD3 ganglioside. Peptides. 1999, 20: 1021-1026. 10.1016\/S0196-9781(99)00095-9.","journal-title":"Peptides"},{"key":"148_CR25","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1046\/j.1440-1711.2000.00949.x","volume":"78","author":"C Natale","year":"2000","unstructured":"Natale C, Giannini T, Lucchese A, Kanduc D: Computer-assisted analysis of molecular mimicry between HPV16 E7 oncoprotein and human protein sequences. Immunol Cell Biol. 2000, 78: 580-585. 10.1046\/j.1440-1711.2000.00949.x.","journal-title":"Immunol Cell Biol"},{"key":"148_CR26","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1002\/ijc.10259","volume":"98","author":"A Mittelman","year":"2002","unstructured":"Mittelman A, Lucchese A, Sinha AA, Kanduc D: Monoclonal and polyclonal humoral immune response to EC HER-2\/NEU peptides with low similarity to the host's proteome. Int J Cancer. 2002, 98: 741-747. 10.1002\/ijc.10259.","journal-title":"Int J Cancer"},{"key":"148_CR27","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1002\/ijc.20310","volume":"111","author":"R Dummer","year":"2004","unstructured":"Dummer R, Mittelman A, Fanizzi FP, Lucchese G, Willers J, Kanduc D: Non-self-discrimination as a driving concept in the identification of an immunodominant HMW-MAA epitopic peptide sequence by autoantibodies from melanoma cancer patients. Int J Cancer. 2004, 111: 720-726. 10.1002\/ijc.20310.","journal-title":"Int J Cancer"},{"key":"148_CR28","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.peptides.2003.12.004","volume":"25","author":"D Kanduc","year":"2004","unstructured":"Kanduc D, Fanizzi FP, Lucchese G, Stevanovic S, Sinha AA, Mittelman A: NMR probing of in silico identification of anti-HPV16 E7 mAb linear peptide epitope. Peptides. 2004, 25: 243-250. 10.1016\/j.peptides.2003.12.004.","journal-title":"Peptides"},{"key":"148_CR29","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1111\/j.0022-202X.2004.23417.x","volume":"123","author":"A Mittelman","year":"2004","unstructured":"Mittelman A, Tiwari R, Lucchese G, Willers J, Dummer R, Kanduc D: Identification of Monoclonal Anti-HMW-MAA Antibody Linear Peptide Epitope by Proteomic Database Mining. J Invest Dermat. 2004, 123: 670-675. 10.1111\/j.0022-202X.2004.23417.x.","journal-title":"J Invest Dermat"},{"key":"148_CR30","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1111\/j.0906-6705.2005.00327.x","volume":"14","author":"J Willers","year":"2005","unstructured":"Willers J, Lucchese A, Mittelman A, Dummer R, Kanduc D: Definition of anti-tyrosinase MAb T311 linear determinant by proteome-based similarity analysis. Exp Dermatol. 2005, 14: 543-50. 10.1111\/j.0906-6705.2005.00327.x.","journal-title":"Exp Dermatol"},{"key":"148_CR31","doi-asserted-by":"publisher","first-page":"7009","DOI":"10.4049\/jimmunol.175.10.7009","volume":"175","author":"A Lucchese","year":"2005","unstructured":"Lucchese A, Willers J, Mittelman A, Kanduc D, Dummer R: Proteomic scan for tyrosinase peptide antigenic pattern in vitiligo and melanoma. Role of sequence similarity and HLA-DR1 affinity. J Immunol. 2005, 175: 7009-7020.","journal-title":"J Immunol"},{"key":"148_CR32","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/1479-5876-2-43","volume":"2","author":"A Lucchese","year":"2004","unstructured":"Lucchese A, Mittelman A, Lin MS, Kanduc D, Sinha AA: Epitope definition by proteomic similarity analysis: identification of the linear determinant of the anti-Dsg3 MAb 5H10. J Transl Med. 2004, 2: 43-10.1186\/1479-5876-2-43.","journal-title":"J Transl Med"},{"key":"148_CR33","first-page":"1","volume":"5","author":"G Angelini","year":"2005","unstructured":"Angelini G, Bonamonte D, Lin MS, Lucchese A, Mittelman A, Serpico R, Simone S, Sinha AA, Kanduc D: Characterization of polyclonal antibodies raised against a linear peptide determinant of desmoglein-3. J Exp Ther Oncol. 2005, 5: 1-7.","journal-title":"J Exp Ther Oncol"},{"key":"148_CR34","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/1479-5876-4-37","volume":"4","author":"A Lucchese","year":"2006","unstructured":"Lucchese A, Mittelman A, Tessitore L, Serpico R, Sinha AA, Kanduc D: Proteomic definition of a desmoglein linear determinant common to Pemphigus vulgaris and Pemphigus foliaceous. J Transl Med. 2006, 4: 37-10.1186\/1479-5876-4-37.","journal-title":"J Transl Med"},{"key":"148_CR35","first-page":"A6","volume":"122","author":"VK Salato","year":"2004","unstructured":"Salato VK, Foegen MK, Lazarova Z, Fairley JA, Lin MS: The role of intra-molecular epitope spreading in the development and transition of pemphigus vulgaris. J Invest Dermatol. 2004, 122: A6-Abstr 031.","journal-title":"J Invest Dermatol"},{"key":"148_CR36","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1358\/dnp.2000.13.2.858466","volume":"13","author":"I Krause","year":"2000","unstructured":"Krause I, Blank M, Shoenfeld Y: Peptide immunotherapy in autoimmune diseases. Drug News Perspect. 2000, 13: 78-84. 10.1358\/dnp.2000.13.2.858466.","journal-title":"Drug News Perspect"},{"key":"148_CR37","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1517\/14712598.3.4.617","volume":"3","author":"M Tarzi","year":"2003","unstructured":"Tarzi M, Larch\u00e9 M: Peptide immunotherapy for allergic disease. Expert Opin Biol Ther. 2003, 3: 617-626. 10.1517\/14712598.3.4.617.","journal-title":"Expert Opin Biol Ther"},{"key":"148_CR38","doi-asserted-by":"publisher","first-page":"2990","DOI":"10.1172\/JCI118371","volume":"96","author":"RR Singh","year":"1995","unstructured":"Singh RR, Ebling FM, Sercarz EE, Hahn BH: Immune tolerance to autoantibody-derived peptides delays development of autoimmunity in murine lupus. J Clin Invest. 1995, 96: 2990-2996.","journal-title":"J Clin Invest"},{"key":"148_CR39","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1046\/j.1365-2567.1999.00721.x","volume":"96","author":"C Jouanne","year":"1999","unstructured":"Jouanne C, Avrameas S, Payelle Brogard B: A peptide derived from a polyreactive monoclonal anti-DNA natural antibody can modulate lupus development in (NZBxNZW) F1 mice. Immunology. 1999, 96: 333-339. 10.1046\/j.1365-2567.1999.00721.x.","journal-title":"Immunology"},{"key":"148_CR40","doi-asserted-by":"publisher","first-page":"8810","DOI":"10.1073\/pnas.0603201103","volume":"103","author":"A Sharabi","year":"2006","unstructured":"Sharabi A, Zinger H, Zborowsky M, Sthoeger ZM, Mozes E: A peptide based on the complementarity-determining region 1 of an autoantibody ameliorates lupus by up-regulating CD4+CD25+ cells and TGF-beta. Proc Natl Acad Sci USA. 2006, 103: 8810-8815. 10.1073\/pnas.0603201103.","journal-title":"Proc Natl Acad Sci USA"},{"key":"148_CR41","doi-asserted-by":"publisher","first-page":"3523","DOI":"10.1016\/j.vaccine.2004.05.006","volume":"22","author":"J Villen","year":"2004","unstructured":"Villen J, Oliveira EdE, Nunez JI, Molina N, Sobrino F, Andreu D: Towards a multi-site synthetic vaccine to foot-and-mouth disease: addition of discontinuous site peptide mimic increases the neutralization response in immunized animals. Vaccine. 2004, 22: 3523-3529. 10.1016\/j.vaccine.2004.05.006.","journal-title":"Vaccine"},{"key":"148_CR42","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1111\/j.1365-2249.2004.02521.x","volume":"137","author":"DJ Jackson","year":"2004","unstructured":"Jackson DJ, Elson CJ, Kumpel BM: Reduction of human anti-tetanus toxoid antibody in hu-PBL-SCID mice by immunodominant peptides of tetanus toxoid. Clin Exp Immunol. 2004, 137: 245-252. 10.1111\/j.1365-2249.2004.02521.x.","journal-title":"Clin Exp Immunol"},{"key":"148_CR43","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1159\/000024403","volume":"122","author":"BM Haselden","year":"2000","unstructured":"Haselden BM, Kay AB, Larch\u00e9 M: Peptide-mediated immune responses in specific immunotherapy. Int Arch Allergy Immunol. 2000, 122: 229-237. 10.1159\/000024403.","journal-title":"Int Arch Allergy Immunol"},{"key":"148_CR44","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.1002\/1521-4141(200006)30:6<1638::AID-IMMU1638>3.0.CO;2-R","volume":"30","author":"C von Garnier","year":"2000","unstructured":"von Garnier C, Astori M, Kettner A, Dufour N, Heusser C, Corradin G, Spertini F: Allergen-derived long peptide immunotherapy down-regulates specific IgE response and protects from anaphylaxis. Eur J Immunol. 2000, 30: 1638-1645. 10.1002\/1521-4141(200006)30:6<1638::AID-IMMU1638>3.0.CO;2-R.","journal-title":"Eur J Immunol"},{"key":"148_CR45","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1615\/CritRevImmunol.v20.i6.20","volume":"20","author":"MH Wauben","year":"2000","unstructured":"Wauben MH: Immunological mechanisms involved in experimental peptide immunotherapy of T-cell-mediated diseases. Crit Rev Immunol. 2000, 20: 451-469.","journal-title":"Crit Rev Immunol"},{"key":"148_CR46","doi-asserted-by":"publisher","first-page":"24141","DOI":"10.1074\/jbc.M313210200","volume":"279","author":"R Sundaram","year":"2004","unstructured":"Sundaram R, Lynch MP, Rawale SV, Sun Y, Kazanji M, Kaumaya PT: De novo design of peptide immunogens that mimic the coiled coil region of human T-cell leukemia virus type-1 glycoprotein 21 transmembrane subunit for induction of native protein reactive neutralizing antibodies. J Biol Chem. 2004, 279: 24141-24151. 10.1074\/jbc.M313210200.","journal-title":"J Biol Chem"},{"key":"148_CR47","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1093\/infdis\/173.2.330","volume":"173","author":"GJ Gorse","year":"1996","unstructured":"Gorse GJ, Keefer MC, Belshe RB, Matthews TJ, Forrest BD, Hsieh RH, Koff WC, Hanson CV, Dolin R, Weinhold KJ, Frey SE, Ketter N, Fast PE: A dose-ranging study of a prototype synthetic HIV-1MN V3 branched peptide vaccine. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group. J Infect Dis. 1996, 173: 330-339.","journal-title":"J Infect Dis"},{"key":"148_CR48","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1016\/j.vaccine.2003.10.014","volume":"22","author":"B Langhans","year":"2004","unstructured":"Langhans B, Braunschweiger I, Schweitzer S, Sauerbruch T, Spengler U: Primary immunisation of hepatitis C virus (HCV)-specific antibody producing B cells by lipidated peptides. Vaccine. 2004, 22: 1441-1447. 10.1016\/j.vaccine.2003.10.014.","journal-title":"Vaccine"},{"key":"148_CR49","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1038\/nrn938","volume":"3","author":"D Schenk","year":"2002","unstructured":"Schenk D: Opinion: amyloid-beta immunotherapy for Alzheimer's disease: the end of the beginning. Nat Rev Neurosci. 2002, 3: 824-828. 10.1038\/nrn938.","journal-title":"Nat Rev Neurosci"},{"key":"148_CR50","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/S0065-3527(01)56008-X","volume":"56","author":"SD Miller","year":"2001","unstructured":"Miller SD, Katz-Levy Y, Neville KL, Vanderlugt CL: Virus-induced autoimmunity: epitope spreading to myelin autoepitopes in Theiler's virus infection of the central nervous system. Adv Virus Res. 2001, 56: 199-217.","journal-title":"Adv Virus Res"},{"key":"148_CR51","doi-asserted-by":"publisher","first-page":"6564","DOI":"10.4049\/jimmunol.169.11.6564","volume":"169","author":"J Tian","year":"2002","unstructured":"Tian J, Olcott AP, Kaufman DL: Antigen-based immunotherapy drives the precocious development of autoimmunity. J Immunol. 2002, 169: 6564-6569.","journal-title":"J Immunol"},{"key":"148_CR52","doi-asserted-by":"publisher","first-page":"580","DOI":"10.4049\/jimmunol.164.2.580","volume":"164","author":"EM Janssen","year":"2000","unstructured":"Janssen EM, van Oosterhout AJ, van Rensen AJ, van Eden W, Nijkamp FP, Wauben MH: Modulation of Th2 responses by peptide analogues in a murine model of allergic asthma: amelioration or deterioration of the disease process depends on the Th1 or Th2 skewing characteristics of the therapeutic peptide. J Immunol. 2000, 164: 580-588.","journal-title":"J Immunol"},{"key":"148_CR53","doi-asserted-by":"publisher","first-page":"11935","DOI":"10.1073\/pnas.92.25.11935","volume":"92","author":"KW Wucherpfennig","year":"1995","unstructured":"Wucherpfennig KW, Yu B, Bhol K, Monos DS, Argyris E, Karr RW, Ahmed AR, Strominger JL: Structural basis for major histocompatibility complex (MHC)-linked susceptibility to autoimmunity: charged residues of a single MHC binding pocket confer selective presentation of self-peptides in pemphigus vulgaris. Proc Natl Acad Sci USA. 1995, 92: 11935-11939. 10.1073\/pnas.92.25.11935.","journal-title":"Proc Natl Acad Sci USA"},{"key":"148_CR54","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1745-7580-2-1","volume":"2","author":"JC Tong","year":"2006","unstructured":"Tong JC, Bramson J, Kanduc D, Chow S, Sinha AA, Ranganathan S: Modeling the bound conformation of Pemphigus Vulgaris-associated peptides to MHC Class II DR and DQ Alleles. Immunome Res. 2006, 2: 1-10.1186\/1745-7580-2-1.","journal-title":"Immunome Res"},{"key":"148_CR55","doi-asserted-by":"publisher","first-page":"3883","DOI":"10.4049\/jimmunol.172.6.3883","volume":"172","author":"CM Veldman","year":"2004","unstructured":"Veldman CM, Gebhard KL, Uter W, Wassmuth R, Grotzinger J, Schultz E, Hertl M: T cell recognition of desmoglein 3 peptides in patients with pemphigus vulgaris and healthy individuals. J Immunol. 2004, 172: 3883-3892.","journal-title":"J Immunol"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1479-5876-4-43.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T01:50:03Z","timestamp":1630461003000},"score":1,"resource":{"primary":{"URL":"https:\/\/translational-medicine.biomedcentral.com\/articles\/10.1186\/1479-5876-4-43"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,6]]},"references-count":55,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2006,6]]}},"alternative-id":["148"],"URL":"https:\/\/doi.org\/10.1186\/1479-5876-4-43","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,6]]},"assertion":[{"value":"28 August 2006","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 October 2006","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 October 2006","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"43"}}